CURRENT JOB POSITION AND ORGANIZATION Professor of Hematology - Humanitas University Milan, Italy Head, Leukemia Unit - Cancer Center - IRCCS Humanitas Research Hospital www.humanitas.it; www.hunimed.eu Head - Center for Accelerating Leukemia/Lymphoma Research – CALR Humanitas AI center, Milan Italy www.humanitas.eu; www.humanitas.eu/calr/ PROFESSIONAL SUMMARY Current research interests mainly concern myeloid malignancies (myelodysplastic syndromes, MDS acute myeloid leukemias AML, myeloproliferative neoplasms, MPN): - Genomics of myeloid neoplasms - Diagnosis and prognostication of myeloid neoplasms - Personalized medicine - Artificial Intelligence in hematology - Decision Support Systems

Dr. Amy DeZern is a hematologist and an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. Dr. DeZern’s primary clinical and research interests are focused on bone marrow failure disorders. She has expertise in the diagnosis and treatment of aplastic anemia (AA), myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) as well as acute leukemias. She is an active clinician scientist who specializes in clinical trials of diagnostics and therapeutics for these disorders. She has been the principle investigator for over 40 single center and multicenter clinical trials in MDS and AA. These investigator-led initiatives focus is on transplant therapies in AA (including the upcoming BMT CTN upfront trial for SAA) and novel therapeutics (Phase 1-3 trials) in MDS. Additionally, Dr. DeZern is the deputy co-chair of The National MDS Study.

I am a Biochemist and Molecular Biologist (University of the Basque Country, 2015-19) specialised in Basic and Translational Research in Cancer (MSc in Biomedicine, University of Barcelona, 2019-20). I am currently doing my PhD studies in Applied Medicine and Biomedicine, at University of Navarra (2020-ongoing), in the fields of Computational Biology and Hemato-Oncology. Concretely, my project is based on identifying transcriptional alterations in MDS and AML that could serve as potential therapeutic targets for these patients.

After graduating from medical school in 1999, Prof. Díez Campelo started medical training in Hematology. Since 2005, she has been working at the Department of Hematology at the University Hospital of Salamanca, IBSAL in Spain. Between 2006 and 2009 she completed a 3-year postdoctoral fellowship provided by ISCII. From 2009 was responsible of the section of Morphology and Hematimetry in the Hematology Department and since 2017 Prof. Díez Campelo held a position of Associate Professor of Hematology at the University of Salamanca in Spain. Since October 2016 Prof. Díez Campelo is heading the Myelodysplastic Syndromes team at the University Hospital in Salamanca. Prof. Díez Campelo´s clinical expertise lies in hematological malignancies with a focus on MDS and AML. The main scientific interest involves the translational exploration of innovative treatment options for these patients. She is a member of the Spanish MDS group (GESMD) since 2009 and head of GESMD since 2018. She also is involved in the European Myelodysplastic Syndromes Cooperative Group (EMSCO).

Dr. DiNardo is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups. Dr. DiNardo has experience in designing, overseeing, and executing successful clinical trials; from Phase 1 dose-finding studies, to innovative investigator-initiated Phase II trials, to confirmatory Phase III trials. Dr. DiNardo has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).

Jacqueline Dubow is an MDS patient. From 2018 to 2021, she was the Vice President of a non-profit, «Connaître et Combattre les Myélodisplasies» (CCM), the sole MDS patient association in France. She was also a member of the MDS Alliance (MDSA) steering Committee. Since April 2022, she is the Chair of the MDSA. The MDSA is an international umbrella regrouping 42 MDS patients associations worldwide. Jacqueline is also a representative within the European Patient Advocacy Groups (ePAGs) that brings together 300+ patient representatives from 28 European countries. The ePAGs represent the patient voice in the European Reference Networks (ERNs). For 40 years, Jacqueline worked in International Developmen. She held senior position with the World Bank Group in Washington, DC. She has advised governments and companies on both operational and strategic matters, principally in the health, education, new technologies and transport sectors Prior working at the World Bank, she designed HIV/AIDS prevention communication strategies in Africa for the World Health Organization and managed a worldwide HIV/AIDS communication and behavioral change program for Family Health International, a U.S. non-profit organization.

Nicolas Duployez is assistant professor in Hematology in Lille, France. He heads the laboratory of molecular genetics of hematological malignancies at the University Hospital of Lille. His current work focuses on the molecular alterations that drive acute myeloid leukemia and myelodysplastic syndromes, germline genetic predisposition factors and molecular markers to predict disease progression and therapeutic response.